"Peptidyl-Dipeptidase A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, -Xaa-*-Xbb-Xcc, when neither Xaa nor Xbb is Pro. It is a Cl(-)-dependent, zinc glycoprotein that is generally membrane-bound and active at neutral pH. It may also have endopeptidase activity on some substrates. (From Enzyme Nomenclature, 1992)
| Descriptor ID |
D007703
|
| MeSH Number(s) |
D08.811.277.656.350.350.687
|
| Concept/Terms |
Peptidyl-Dipeptidase A- Peptidyl-Dipeptidase A
- Peptidyl Dipeptidase A
- Angiotensin I-Converting Enzyme
- Angiotensin I Converting Enzyme
- Carboxycathepsin
- CD143 Antigens
- Kininase II
- Dipeptidyl Peptidase A
- Antigens, CD143
- Angiotensin Converting Enzyme
- Kininase A
|
Below are MeSH descriptors whose meaning is more general than "Peptidyl-Dipeptidase A".
Below are MeSH descriptors whose meaning is more specific than "Peptidyl-Dipeptidase A".
This graph shows the total number of publications written about "Peptidyl-Dipeptidase A" by people in this website by year, and whether "Peptidyl-Dipeptidase A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 4 | 0 | 4 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 3 | 0 | 3 |
| 2008 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 3 | 0 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 1 | 3 |
| 2020 | 9 | 6 | 15 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Peptidyl-Dipeptidase A" by people in Profiles.
-
CDK4/6 inhibitor palbociclib promotes SARS-CoV-2?cell entry by down-regulating SKP2 dependent ACE2 degradation. Antiviral Res. 2023 04; 212:105558.
-
Incidence of an Insulin-Requiring Hyperglycemic Syndrome in SARS-CoV-2-Infected Young Individuals: Is It Type 1 Diabetes? Diabetes. 2022 12 01; 71(12):2656-2663.
-
Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2. J Food Biochem. 2022 10; 46(10):e14354.
-
Exercise-induced myokines downregulates the ACE2 level in bronchial epithelial cells: Implications for SARS-CoV-2 prevention. PLoS One. 2022; 17(7):e0271303.
-
Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2. J Transl Med. 2022 07 14; 20(1):314.
-
Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. Nat Biotechnol. 2022 08; 40(8):1270-1275.
-
Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis. PLoS Med. 2022 02; 19(2):e1003897.
-
Angiotensin-converting enzyme 2 decreased expression during kidney inflammatory diseases: implications to predisposing to COVID-19 kidney complications. Kidney Int. 2021 11; 100(5):1138-1140.
-
"Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry. Int J Mol Sci. 2021 Aug 20; 22(16).
-
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. J Thorac Oncol. 2021 11; 16(11):1821-1839.